Business
Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020
HOUSTON, May 4, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, May 4, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m. Eastern Time to review its first quarter 2020 financial and operating results and provide a corporate update.\n\n \n \n \n \n \n \n\n \nThe webcast will be accessible in the Investors section of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the \"Marker Therapeutics First Quarter 2020 Earnings Call.\"\nThe archived webcast will be available for replay on the Marker website following the event.\nAbout Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.\nTo receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts\nForward-Looking Statement DisclaimerThis release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this new...